Major cancer study into impact of frailty | News

Royal Surrey researchers have led a major study showing that a simple digital measure of frailty could help doctors better decide whether chemotherapy is appropriate for patients.

The study analysed health data from nearly 79,000 cancer patients across England and found that the Secondary Care Administrative Records Frailty (SCARF) Index can help predict survival and early mortality, particularly in patients with breast and colorectal cancer.

Led by Professor Agnieszka Michael and colleagues at both Royal Surrey and the University of Surrey, the research showed that patients identified as frail using the SCARF index were significantly more likely to experience poorer outcomes following chemotherapy.

Unlike traditional assessments of frailty, which rely largely on how physically active a patient appears, the SCARF index draws on routinely collected hospital data. 

The findings have been published in The British Journal of Cancer in a paper titled The utility of an electronic frailty index in cancer patients undergoing chemotherapy.

Professor Michael said: “Frailty is often under-recognised in oncology and traditional tools don’t always capture the whole picture of a patient.

“Digital tools like SCARF can help clinicians better match treatment to the individual and support more open, informed conversations about the risks and benefits of chemotherapy. 

“While there is more work to do, this represents an important step towards making frailty visible, measurable and actionable in everyday cancer care.”